World's Best Scientists 2026 revealed!

D-Index & Metrics

Biology and Biochemistry

D-Index
68
Citations
17594
World Ranking
7745
National Ranking
55

Overview

Satu Mustjoki is affiliated with the University of Helsinki in Finland, focusing their research primarily in the fields of Medicine and Immunology and Microbiology. Their work encompasses several specialized subfields including Immunology, Oncology, Hematology, Genetics, and Molecular Biology.

The main topics covered in their research include:

  • Immune Cell Function and Interaction
  • Chronic Lymphocytic Leukemia Research
  • CAR-T Cell Therapy Research
  • Chronic Myeloid Leukemia Treatments
  • Acute Myeloid Leukemia Research
  • T-cell and B-cell Immunology
  • Cancer Immunotherapy and Biomarkers

The scientist has published frequently in a number of journals, with prominent venues including:

  • Blood
  • bioRxiv (Cold Spring Harbor Laboratory)
  • Leukemia
  • Cancer Research
  • HemaSphere

Among their recent publications are:

  • "Immunogenomic Landscape of Hematological Malignancies," 2020, Cancer Cell
  • "Implementing a Functional Precision Medicine Tumor Board for Acute Myeloid Leukemia," 2021, Cancer Discovery
  • "Somatic Mutations in "Benign" Disease," 2021, New England Journal of Medicine
  • "Immune cell constitution in the tumor microenvironment predicts the outcome in diffuse large B-cell lymphoma," 2020, Haematologica
  • "Predicting recognition between T cell receptors and epitopes with TCRGP," 2021, PLoS Computational Biology

Frequent co-authors with whom they have collaborated extensively include:

  • Jani Huuhtanen
  • Olli Dufva
  • Matti Kankainen
  • Jay Klievink
  • Oscar Brück

Best Publications

  • Isolated lymphatic endothelial cells transduce growth, survival and migratory signals via the VEGF‐C/D receptor VEGFR‐3

    Taija Mäkinen;Tanja Veikkola;Satu Mustjoki;Terhi Karpanen

  • Somatic STAT3 Mutations in Large Granular Lymphocytic Leukemia

    Hanna L.M. Koskela;Samuli Eldfors;Pekka Ellonen;Arjan J. van Adrichem

  • VEGFR-3 and CD133 identify a population of CD34+ lymphatic/vascular endothelial precursor cells

    Petri Salven;Satu Mustjoki;Satu Mustjoki;Riitta Alitalo;Riitta Alitalo;Kari Alitalo;Kari Alitalo

  • Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial

    Susanne Saussele;Johan Richter;Joelle Guilhot;Franz X Gruber

  • Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia.

    Kimmo Porkka;Perttu Koskenvesa;Tuija Lundán;Johanna Rimpiläinen

  • Activating germline mutations in STAT3 cause early-onset multi-organ autoimmune disease

    Sarah E Flanagan;Emma Haapaniemi;Mark A Russell;Richard Caswell

  • STAT3 mutations unify the pathogenesis of chronic lymphoproliferative disorders of NK cells and T-cell large granular lymphocyte leukemia

    Andres Jerez;Michael J. Clemente;Hideki Makishima;Hanna Koskela

  • Individualized Systems Medicine Strategy to Tailor Treatments for Patients with Chemorefractory Acute Myeloid Leukemia

    Tea Pemovska;Mika Kontro;Bhagwan Yadav;Henrik Edgren

  • Single-cell transcriptomics uncovers distinct molecular signatures of stem cells in chronic myeloid leukemia

    Alice Giustacchini;Supat Thongjuea;Nikolaos Barkas;Petter S Woll

  • Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy

    S. Mustjoki;M. Ekblom;T. P. Arstila;I. Dybedal

  • Discovery of somatic STAT5b mutations in large granular lymphocytic leukemia

    Hanna L. M. Rajala;Samuli Eldfors;Heikki Kuusanmäki;Arjan J. van Adrichem

  • Autoimmunity, hypogammaglobulinemia, lymphoproliferation, and mycobacterial disease in patients with activating mutations in STAT3.

    Emma M. Haapaniemi;Meri Kaustio;Hanna L. M. Rajala;Arjan J. van Adrichem

  • Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia.

    M Ilander;Ulla Olsson-Strömberg;Ulla Olsson-Strömberg;H Schlums;J Guilhot

  • Combination of pegylated IFN-α2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia

    Bengt Simonsson;Tobias Gedde-Dahl;Berit Markevärn;Kari Remes

  • Integrated drug profiling and CRISPR screening identify essential pathways for CAR T-cell cytotoxicity.

    Olli Dufva;Jan Koski;Pilvi Maliniemi;Aleksandr Ianevski;Aleksandr Ianevski

  • Mono/oligoclonal T and NK cells are common in chronic myeloid leukemia patients at diagnosis and expand during dasatinib therapy

    Anna Kreutzman;Vesa Juvonen;Veli Kairisto;Marja Ekblom

  • STAT3 mutations indicate the presence of subclinical T-cell clones in a subset of aplastic anemia and myelodysplastic syndrome patients

    Andres Jerez;Michael J. Clemente;Hideki Makishima;Hanna Rajala

  • Immunogenomic Landscape of Hematological Malignancies

    Olli Dufva;Olli Dufva;Petri Pölönen;Oscar Brück;Oscar Brück;Mikko A.I. Keränen

  • Single-cell molecular analysis defines therapy response and immunophenotype of stem cell subpopulations in CML

    Rebecca Warfvinge;Linda Geironson;Mikael N. E. Sommarin;Stefan Lang

  • Clonal Expansion of T/NK-Cells during Tyrosine Kinase Inhibitor Dasatinib Therapy

    Satu Mustjoki;Marja Ekblom;T. Petteri Arstila;Ingunn Dybedal

Frequent Co-Authors

Kimmo Porkka
Kimmo Porkka University of Helsinki
Olli Kallioniemi
Olli Kallioniemi Karolinska Institute
Tero Aittokallio
Tero Aittokallio University of Helsinki
Bjørn Tore Gjertsen
Bjørn Tore Gjertsen Haukeland University Hospital
Andreas Hochhaus
Andreas Hochhaus Friedrich Schiller University Jena
Jaroslaw P. Maciejewski
Jaroslaw P. Maciejewski Cleveland Clinic
Thomas P. Loughran
Thomas P. Loughran University of Virginia
Janna Saarela
Janna Saarela University of Helsinki
Juha Kere
Juha Kere Karolinska Institute
Tim H. Brümmendorf
Tim H. Brümmendorf RWTH Aachen University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you are passionate about Biology and Biochemistry, there are a variety of online degrees in related health sciences to help expand your expertise and career options. Many students choose to pursue specialized programs that blend technical skills with life sciences, enhancing their employability in the healthcare sector.

For those interested in managing medical data, a health information management online degree can open doors to roles in data security and patient records management. Nutrition is another growing field—consider earning the cheapest online nutrition degree to gain deeper knowledge in dietetics and wellness.

Technology-focused students can explore healthcare imaging by enrolling in ultrasound tech programs online, or consider radiation sciences with the cheapest radiology tech programs. These paths offer hands-on, in-demand skills and fast-track pathways into clinical roles.

Exploring these online degrees provides you with flexible options to build a rewarding career that complements your studies in Biology and Biochemistry.

Best Scientists Citing Satu Mustjoki

Trending Scientists

Recently Published Articles